Abstract: TH-PO223
The Prognostic Value of Serum Galectin 3 to Abdominal Aortic Calcification Progression in Maintenance Hemodialysis Patients
Session Information
- Bone and Mineral Metabolism: Clinical - I
October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 402 Bone and Mineral Metabolism: Clinical
Authors
- Wang, Zhiyu, Dapartment of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- Chen, Zijin, Ruijin Hospital affilliated to Shanghai Jiaotong University, Shanghai, SHanghai, China
- Yu, Haijin, Division of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China
- Chen, Xiaonong, Division of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China
Background
Heterotopic vascular calcification is one of the complications of maintenance hemodialysis (MHD) patients contributed to adverse prognosis. Basic research results indicated the relation of Galectin-3 (Gal-3) with cardiovascular calcification. However whether serum Gal-3 is associated with uremic vascular calcification has not been investigated yet.
Methods
A prospective cohort study was performed. Eligible patients undergoing hemodialysis during July 2014 enrolled from Blood Purification Center of Ruijin Hospital were followed up for 3 years. Twice AAC assessment have been performed at the baseline and after 3-year follow-up respectively. Baseline laboratory measurement results, clinical data and blood samples were collected. Serum Gal-3 was detected by quantified ELISA kits. SPSS 23.0 and Medcalc 11.4.2.0 were used to analyze data.
Results
152 patients were recruited. Mean Gal-3 concentration was 29.24±10.15ng/ml. All patients has finished first lateral lumbar X-ray examination and 104 patients finished repetitive examination 3 years later. Serum Gal-3 was positively associated with blood phosphonium, baseline abdominal aortic calcification score (AACS), andΔAACS of MHD patients. Logistic regression analysis indicated that serum Gal-3 was an independent risk factor to both severe AAC and AAC progression in 3 years. ROC analysis revealed a significant prognostic value of serum Gal-3 to severe AAC and AAC progression in 3 years. High serum Gal-3 was one of the characteristics of patients with rapid AAC progression.
Conclusion
Serum Gal-3 is a novel biomarker of vascular calcification in uremic patients. Our research first demonstrated that serum Gal-3 was a promising biomarker predicting severe AAC and AAC progression in 3years of MHD patients. Serum Gal-3 maybe a potential intervention target for vascular calcification of MHD patients.
Funding
- Government Support - Non-U.S.